Zenocutuzumab (a HER2/HER3 BSAB) is an orphan drug for NRG1+ pancreatic ductal adenocarcinoma (ORR, 39%) [96]. This evidence concerns the gene ERBB3 and pancreatic ductal adenocarcinoma.